Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera(R) ceftobiprole.

Innoviva Specialty Therapeutics has signed an exclusive distribution and licensing agreement with Basilea Pharmaceutica Ltd for the U.S. marketing rights of Zevtera (ceftobiprole), an advanced-generation cephalosporin antibiotic. Zevtera is the only FDA-approved methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin antibiotic for specific treatment indications, including Staphylococcus aureus bloodstream infections and endocarditis. The agreement grants Innoviva exclusive marketing rights for Zevtera in the U.S., with plans to commercialize the drug in mid-year 2025. [Extracted from the article]